BTIG raised the firm’s price target on Globus Medical (GMED) to $87 from $78 and keeps a Buy rating on the shares after its Q3 earnings beat and guidance raise. The company is disproving any and all preconceived notions of why spine mergers cannot work, the analyst tells investors in a research note. Globus Medical’s financial discipline and operational execution are also creating a flywheel effect likely to yield significant free cash flow conversion that will ultimately drive share buybacks, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $80 from $55 at BofA
- Globus Medical price target raised to $88 from $78 at Wells Fargo
- Globus Medical Reports Robust Q3 2024 Financial Growth
- Closing Bell Movers: Exact Sciences falls 30% after results, guidance cut
- Globus Medical raises FY24 EPS view to $2.90-$3.00 from $2.80-$2.90